Corvus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRVS research report →
Range $27 – $27
Price Chart
About the company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers.
- CEO
- Richard A. Miller
- IPO
- 2016
- Employees
- 37
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on CRVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $815.69M
- P/E
- -13.07
- Fwd P/E
- 65.93
- PEG
- 0.08
- P/S
- 0.00
- P/B
- 4.29
- EV/EBITDA
- -12.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -34.98%
- ROIC
- -32.42%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-105,000+0.0%
- Op Income
- $-42,971,000
- Net Income
- $-15,283,000+75.5%
- EPS
- $-0.19+81.4%
- OCF Growth
- -29.0%
- FCF Growth
- -29.7%
- 52W High
- $26.95
- 52W Low
- $6.39
- 50D MA
- $10.91
- 200D MA
- $13.78
- Beta
- 0.86
- RSI (14)
- 40
- Avg Volume
- 1.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Corvus said soquelitinib remains on track across multiple programs, with cash runway into the second quarter of 2028 and several 2027 catalysts ahead.· November 5, 2026
- Q3 2026 R&D expense rose to $17.8 million from $8.5 million a year ago, driving a net loss of $20.3 million versus $10.2 million.
- Cash, cash equivalents and marketable securities were $202.9 million at September 30, 2026, up from $56.8 million at year-end 2025; management expects runway into Q2 2028.
- Lead programs in relapsed/refractory PTCL and atopic dermatitis are both described as on track, with PTCL futility analysis due in Q1 2027 and AD top-line data in Q3 2027.
- Corvus is expanding soquelitinib into HS and asthma, while ALPS data at ASH support the drug’s safety profile and broader immune activity.
- Management highlighted a broad 2027 catalyst calendar, including Angel AD data, HS results, asthma trial starts, and PTCL top-line data by year-end 2027.
Corvus reported third-quarter 2026 R&D expense of $17.8 million, up from $8.5 million in the same period of 2025. Net loss was $20.3 million versus $10.2 million a year ago; included in net loss were noncash losses of $0.9 million and $0.3 million from its equity method investment in Angel Pharmaceuticals. Stock compensation expense was $2.8 million compared with $1.2 million last year. Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, versus $56.8 million at December 31, 2025, and management said cash should fund operations into the second quarter of 2028. No revenue or EPS figure was stated. Forward-looking milestones include a PTCL futility analysis in Q1 2027, Angel atopic dermatitis cohort 1 data in March 2027, HS Phase 1b data in the first half of 2027, Corvus SEERA-1 Phase 2 data in Q3 2027, Angel cohort 2 data in the second half of 2027, and PTCL top-line data before year-end 2027.
Richard A. Miller framed soquelitinib as the company’s core asset and emphasized a strategy of using its ITK mechanism across several Th2- and Th17-driven diseases. He said the two lead opportunities remain PTCL and atopic dermatitis, both on track, while HS, asthma, and ALPS could broaden the drug’s value proposition. His tone was confident and expansionary, repeatedly stressing a strong 2027 catalyst slate and the potential to generate significant value.
Leiv Lea focused on the quarter’s higher operating spend and the company’s strengthened balance sheet. He said R&D rose to $17.8 million from $8.5 million mainly because of higher clinical trial costs for soquelitinib and increased personnel costs, while the net loss widened to $20.3 million from $10.2 million. He also noted $189.4 million of the cash balance came from the Q1 follow-on offering, plus a $5 million investment in Angel’s $13.5 million financing, and reiterated runway into Q2 2028 based on current plans.
Analysts focused on the timing and interpretation of upcoming data readouts. Management said the Angel atopic dermatitis timeline moved out mainly because they wanted the full 12 weeks of treatment plus 30 days of follow-up before disclosure, and because they are carefully keeping the study blinded; they also said the baseline characteristics in Angel’s first cohort look very similar to Corvus’ Phase 1 AD population. On PTCL, management clarified that the Q1 2027 futility analysis would only disclose whether the study continues or stops, to avoid biasing the trial, while on HS they said they will track lesion-level measures such as nodules, abscesses, and draining tunnels and that efficacy benchmarks around HiSCR 50 and 75 would be important. They also said ALPS is being moved under Corvus to allow expansion into pediatrics and more control of the study, but it is too early to discuss pricing or commercialization.
The company has multiple shots on goal, with a lead asset that already has activity across PTCL, AD, HS, asthma and ALPS, and management said the safety profile has remained favorable. Corvus also pointed to early ALPS response data, strong interest in the HS trial, and the possibility of first-line or later-line use in AD if SEERA-1 is successful.
The quarter showed higher spending and a larger loss, and Corvus remains pre-commercial with no revenue reported. Several key readouts are still ahead, including the PTCL futility decision and AD efficacy data, so the story still depends on upcoming clinical results. Management also acknowledged that if the PTCL interim analysis is unfavorable the study could be stopped, and that many plans, including asthma and ALPS pediatric expansion, are still early-stage.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.0%
- Shares Outstanding
- 84.35M
- Float Shares
- 64.97M
of shares held by institutions
188 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Orbimed Advisors LLC | 7.17M | 0 |
| Blackrock, Inc. | 7.10M | ▼ 38.41K |
| Vanguard Group Inc | 3.87M | ▲ 401.56K |
| Price T Rowe Associates Inc | 3.79M | ▲ 871.83K |
| State Street Corp | 3.33M | ▼ 1.14M |
| Vanguard Capital Management LLC | 3.32M | ▲ 26.36K |
| Adams Street Partners LLC | 3.28M | 0 |
| Vivo Capital, LLC | 2.81M | 0 |
| Wellington Management Group Llp | 2.73M | ▲ 413.12K |
| Perceptive Advisors LLC | 2.67M | ▲ 375.00K |
| Deep Track Capital, LP | 2.49M | ▲ 400 |
| Braidwell LP | 2.13M | ▲ 373.50K |
Held by 225 ETFs
Biggest fund positions in CRVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Arcara Jeffrey | buy | 500 |
| Nov 13, 26 | Arcara Jeffrey | buy | 503 |
| Nov 12, 26 | Arcara Jeffrey | buy | 497 |
| Nov 11, 26 | Arcara Jeffrey | buy | 3,000 |
| Jun 11, 26 | Moore David Scott | buy | 21,700 |
| Jun 11, 26 | Moore David Scott | other | 15,000 |
| Jun 11, 26 | CLARK IAN T | other | 15,000 |
| Jun 11, 26 | Grais Linda | other | 15,000 |
| Jun 11, 26 | Thompson Peter A. | other | 15,000 |
| Jun 11, 26 | van den Broek Richard | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRVS coverage
Recent articles, reports, and earnings notes.
No research on CRVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRVS report →Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product
seekingalpha.com · Nov 10
Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027
seekingalpha.com · Nov 9
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 9
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
globenewswire.com · Nov 4
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 29
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?
defenseworld.net · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.